首页 | 本学科首页   官方微博 | 高级检索  
     

超高效液相色谱-串联质谱法测定人血浆中盐酸氨溴索及其制剂的生物等效性评价
引用本文:贺美莲,郭常川,冷佳薇,张迅杰,咸瑞卿,巩丽萍,石峰,姜玮. 超高效液相色谱-串联质谱法测定人血浆中盐酸氨溴索及其制剂的生物等效性评价[J]. 色谱, 2018, 36(11): 1099-1104. DOI: 10.3724/SP.J.1123.2018.07021
作者姓名:贺美莲  郭常川  冷佳薇  张迅杰  咸瑞卿  巩丽萍  石峰  姜玮
作者单位:1. 山东大学药学院, 山东 济南 250012;2. 山东省食品药品检验研究院, 山东 济南 250101;3. 山东大学化学与化工学院, 山东 济南 250100
基金项目:国家自然科学基金(81573606).
摘    要:采用超高效液相色谱-串联质谱(UHPLC-MS/MS)技术,建立了快速、简单、灵敏的测定人血浆中盐酸氨溴索含量的方法,并用于盐酸氨溴索人体生物等效性预试验研究。取50 μL血浆样品,采用蛋白沉淀法处理,以盐酸氨溴索-d5为内标。采用Waters XBridge BEH C18色谱柱(50 mm×2.1 mm,2.5 μm),以0.1%(v/v)甲酸水-含0.1%(v/v)甲酸的甲醇为流动相,在0.4 mL/min流速下进行梯度洗脱。采用电喷雾电离(ESI)源以正离子模式进行MRM检测。结果显示,盐酸氨溴索在2~400 ng/mL范围内线性关系良好,相关系数(r)为0.998,准确度为97.1%~108.7%,精密度为1.0%~5.6%。将该方法用于6名健康受试者口服盐酸氨溴索受试制剂和参比制剂30 mg后血药浓度的测定,结果显示二者相对生物利用度为(102.3±14.8)%,血药浓度-时间曲线下面积(AUC0-t、AUC0-∞)和最大血药浓度(Cmax)的90%置信区间均在80.0%~125.0%范围内,两种制剂生物等效。

关 键 词:超高效液相色谱-串联质谱  人血浆  生物等效性  盐酸氨溴索  
收稿时间:2018-07-23

Determination of ambroxol hydrochloride in human plasma by ultra high performance liquid chromatography-tandem mass spectrometry and bioequivalence evaluation of its preparation
HE Meilian,GUO Changchuan,LENG Jiawei,ZHANG Xunjie,XIAN Ruiqing,GONG Liping,SHI Feng,JIANG Wei. Determination of ambroxol hydrochloride in human plasma by ultra high performance liquid chromatography-tandem mass spectrometry and bioequivalence evaluation of its preparation[J]. Chinese journal of chromatography, 2018, 36(11): 1099-1104. DOI: 10.3724/SP.J.1123.2018.07021
Authors:HE Meilian  GUO Changchuan  LENG Jiawei  ZHANG Xunjie  XIAN Ruiqing  GONG Liping  SHI Feng  JIANG Wei
Affiliation:1. School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China;2. Shandong Institute for Food and Drug Control, Jinan 250101, China;3. School of Chemistry and Chemical Engineering, Shandong University, Jinan 250100, China
Abstract:A rapid, simple and sensitive ultra high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method was developed for the determination of ambroxol hydrochloride in human plasma, and bioequivalence of its preparation was evaluated. The 50 μL-plasma sample was treated with methanol for protein precipitation, while ambroxol-d5 was used as an internal standard (IS). The separation was carried out on a Waters XBridge BEH C18 column (50 mm×2.1 mm, 2.5 μm) by gradient elution at a flow rate of 0.4 mL/min, with 0.1% (v/v) formic acid aqueous solution and methanol containing 0.1% (v/v) formic acid as the mobile phases. The analyte was detected using an electrospray ionization source in positive ion multiple reaction monitoring (MRM) mode. The calibration curves were linear in the range of 2-400 ng/mL (r=0.998). The intra- and inter-run accuracies were 97.1%-108.7%, the intra- and inter-run precisions were 1.0%-5.6%. The method was applied to the determination of the plasma concentration of the six healthy subjects after the oral administration of 30 mg of test and reference preparations. The bioavailability was (102.3±14.8)%. The 90% confidence intervals of the test preparation's pharmacokinetic parameters were 80.0%-125.0% of the reference preparation's corresponding parameters. Thus, it is proved that the test preparation and reference preparation are bioequivalent.
Keywords:ultra high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS)  bioequivalence  ambroxol hydrochloride  human plasma
本文献已被 CNKI 等数据库收录!
点击此处可从《色谱》浏览原始摘要信息
点击此处可从《色谱》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号